B群脑膜炎球菌疫苗(Bexsero®)安全性监测:疫苗不良事件报告系统,2015-2018年
分析2015年1月23日至2018年12月31日美国疫苗不良事件报告系统(VAERS)中B群脑膜炎球菌疫苗(MenB-4C)的被动监测报告。共收到1,867份报告,相当于每百万剂分发332份报告,96%为非严重报告。未发现新的安全性问题,但需持续上市后监测。
要点
- MenB-4C上市后被动监测共收到1,867份报告,每百万剂分发332份报告。
- 96%的报告为非严重报告,常见不良事件为注射部位疼痛(22%)、发热(16%)和头痛(16%)。
- 数据挖掘发现注射部位反应继发的「注射肢体活动度下降」报告比例超出预期。
核心结论
- 作者认为结果令人安心,但仍需持续上市后监测。
研究设计与样本
- 病例系列分析,数据来源为美国疫苗不良事件报告系统(VAERS)这一全国被动监测系统,分析2015年1月23日至2018年12月31日期间涉及MenB-4C的美国报告。
- VAERS使用《监管活动医学词典》编码报告的不良事件,并使用《联邦法规汇编》对报告按严重性分类。
- 采用经验贝叶斯数据挖掘识别报告频率至少为预期两倍的MenB-4C/不良事件组合。
主要发现
- VAERS共收到1,867份MenB-4C接种后报告,相当于每百万剂分发332份报告。
- 大多数报告为女性(59%),中位年龄17岁(四分位距:16-18岁);40%的报告描述了同时接种其他疫苗。
- 大多数报告被分类为非严重报告(96%)。
- 最常报告的不良事件为注射部位疼痛(22%)、发热(16%)和头痛(16%)。
- 数据挖掘发现注射部位反应继发的「注射肢体活动度下降」报告比例超出预期,包括接种肢体广泛肿胀和注射部位疼痛。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bexsero® (GlaxoSmithKline) is a four-component Neisseria meningitidis serogroup B vaccine (MenB-4C). It was licensed in the United States in 2015 for use among individuals ages 10-25 years. We aimed to assess the post-licensure safety profile of MenB-4C by examining reports received in the Vaccine Adverse Event Reporting System (VAERS). METHODS: VAERS is a national passive surveillance system for adverse events (AEs) following immunization that uses the Medical Dictionary for Regulatory Activities to code reported AEs and the Code of Federal Regulations to classify reports by seriousness. In this case series, we analyzed U.S. reports involving MenB-4C received between January 23, 2015 through December 31, 2018. We used Empirical Bayesian data mining to identify MenB-4C/AE combinations reported at least twice as often as expected. RESULTS: VAERS received 1,867 reports following MenB-4C administration, representing 332 reports per million doses distributed. Most reports were for females (59%), with a median age of 17 years (interquartile range: 16-18 years); 40% of reports described simultaneous administration of other vaccines. The majority of reports were classified as non-serious (96%). The most commonly reported AEs were injection site pain (22%), pyrexia (16%), and headache (16%). Data mining identified disproportionate reporting for "injected limb mobility decreased" secondary to injection site reactions, including extensive swelling of the vaccinated limb and injection site pain. CONCLUSIONS: Analysis of passive surveillance data from over 5.6 million doses of MenB-4C distributed in the United States did not reveal new safety concerns. The large majority of reports were classified as non-serious and the reported AEs were generally consistent with the safety experience described in clinical studies and the product's package insert. While our results are reassuring, continued post-marketing surveillance is warranted.
引用
- Perez-Vilar S, Dores GM, Marquez PL, et al. Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018. Vaccine. 2021. PMID: 34887130. doi:10.1016/j.vaccine.2021.11.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。